Artificial Iris - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The artificial iris market size is expected to grow from USD 22.52 million in 2025 to USD 24.65 million in 2026 and is forecast to reach USD 38.71 million by 2031 at 9.45% CAGR over 2026-2031. This report is Segmented by Implant Type (Custom Artificial Iris, Preformed Artificial Iris), Application (Congenital Aniridia, Traumatic Iris Defects, Surgical Iris Defects, Cosmetic Correction), Distribution Channel (Hospital Procurement, Specialty Distributor, Online Sales), and Geography (North America, Europe, Asia-Pacific, Rest of the World). The Market Forecasts are Provided in Terms of Value (USD).

Global Artificial Iris Market Trends and Insights

Increasing Prevalence of Congenital Aniridia and Traumatic Iris Defects

Congenital aniridia affects an estimated 1 in 40,000 to 1 in 100,000 births globally. More than 50% of affected patients develop secondary glaucoma, while lens opacities occur in 50% to 90% of cases. Nystagmus can accompany up to 95% of cases, and aniridia-associated keratopathy affects 70% to 80% of patients. The combination of these conditions means that many patients require repeated assessment rather than a single device-focused visit. Hospitals must assess corneal health, glaucoma risk, residual iris tissue, lens status, and the expected method of fixation before reconstruction. These clinical needs make coordinated care across anterior-segment, glaucoma, corneal, and low-vision services important. The artificial iris market also serves patients with iris damage after cataract extraction, glaucoma drainage device placement, or penetrating keratoplasty, even when they are not included in congenital prevalence records. Such damage can emerge during treatment for another serious eye condition and may only become apparent after the primary procedure. A 2025 Chinese clinical series was mainly composed of patients with traumatic causes, which supports the importance of this non-congenital pathway.

FDA and CE-Mark Access Expanding Clinical Adoption

The Category I CPT code 66683 became effective on January 1, 2025, replacing the earlier Category III codes 0616T through 0618T for iris prosthesis procedures. The coding change gives clinicians a clearer framework for documenting medically indicated implantation. It separates medically necessary reconstruction from coding arrangements commonly associated with emerging procedures. The change can improve administrative consistency for eligible procedures, although payer policies still vary across plans and patient groups. Some commercial plans continued to consider the device investigational during 2025, which can delay treatment authorization. Documentation of functional symptoms, prior treatment, iris loss, and the intended reconstructive purpose remains important in those reviews. HumanOptics maintained the ARTIFICIALIRIS platform's CE-mark availability through Medical Device Regulation certification in 2025. This regulatory continuity supports supply access in European care settings and raises the evidence and compliance requirements for potential competitors in the artificial iris market.

High Implant and Procedure Cost With Inconsistent Reimbursement

The cost of an iris prosthesis alone typically exceeds USD 1,000. Full treatment costs also include facility use, surgeon time, anesthesia, and postoperative monitoring. Patients may also face the cost of managing glaucoma, corneal disease, or lens complications that affect the same eye. This cost structure places treatment outside the affordable range for many patients in uninsured or under-reimbursed settings. Commercial plans often require prior authorization, and incomplete clinical documentation can delay access. These delays can be particularly difficult when photophobia, glare, or visual disturbance affects daily activities. North America and Western Europe have structured reimbursement pathways, but they do not provide consistent coverage in every case. In Southeast Asia, Latin America, and the Middle East, out-of-pocket payment can limit the artificial iris market to higher-income patients who can access tertiary private care.

Other drivers and restraints analyzed in the detailed report include:

• Preference for Foldable, Minimally Invasive Reconstruction
• Digital Color-Matching and Distributed Custom Manufacturing
• Complex Implantation and Surgeon Learning Curve

Segment Analysis

Custom artificial iris devices held 62.31% of artificial iris market share in 2025. This position reflects the need to address unique iris morphology, partial residual tissue, irregular pupil anatomy, and individualized color patterns in medically indicated reconstruction. It also reflects the importance of restoring a functional pupil aperture when glare and light sensitivity affect a patient's daily visual comfort. Customized devices are made from pigmented, medical-grade, foldable silicone and can reproduce detailed color variation and heterochromatic patterns. They allow the surgeon to select an implant intended to work with the remaining anatomy rather than using a generic visual design. This selection can be especially important where iris loss is incomplete, asymmetric, or combined with lens and corneal disease. The 2026 consensus supported patient-matched design for elective reconstruction and set out 6 evidence-based recommendations for device selection, assessment, and follow-up.

Preformed devices represented a smaller portion of the artificial iris market in 2025. Their importance is growing because urgent, traumatic, and pediatric cases may not permit a 4 to 8 week custom manufacturing period. ARTIFICIALIRIS SELECT provides 9 stock colors for immediate dispatch in eligible cases, offering a defined option for cases where time and access matter. Custom devices remain relevant for elective reconstructions where close color matching, residual iris configuration, and patient expectations require greater individualization. The longer planning period is more practical when the surgeon can defer implantation until the eye has stabilized after earlier treatment. Stock and custom configurations therefore serve different clinical situations rather than simply presenting lower- and higher-priced alternatives.

Complete Report Scope:

• By Implant Type
  • Custom Artificial Iris
  • Preformed or Pre-manufactured Artificial Iris
• By Application
  • Congenital Aniridia
  • Traumatic Iris Defects
  • Surgical Iris Defects
  • Cosmetic Correction
  • Other Applications
• By Distribution Channel
  • Hospital Procurement
  • Specialty Distributor
  • Online Sales
  • Other Distribution Channels
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World

Geography Analysis

North America held 38.61% of global revenue in 2025. The United States supports this position through the FDA-cleared CUSTOMFLEX ARTIFICIALIRIS and a network of high-volume ophthalmology centers that can manage complex anterior-segment reconstruction. The 2025 Category I CPT code for iris prosthesis implantation gave physicians a clearer coding pathway for eligible procedures. VEO Ophthalmics provides a specialist distribution channel in the United States and supports access to surgeons and hospital customers. Canada relies on case-by-case coverage decisions through provincial health authorities, while Mexico remains largely a private-pay setting centered on tertiary urban care.

Europe is the second-largest regional area of the artificial iris market. Germany, the United Kingdom, and France have high concentrations of specialist anterior-segment centers with the surgical equipment and referral patterns needed for these cases. HumanOptics secured Medical Device Regulation certification in 2025, maintaining ARTIFICIALIRIS availability across European Union member states. The Homburg Aniridia Registry in Germany included 337 patients and has provided genetic and systemic clinical evidence used in care planning. Spain, Italy, the Netherlands, Turkey, and Poland show growing or early adoption as training in foldable iris prostheses reaches more surgical centers and referral networks.

Asia-Pacific is forecast to grow at a CAGR of 11.25% through 2031. China is supported by the first peer-reviewed clinical assessment in a Chinese patient population, published in August 2025, which reported significant reductions in photophobia and appearance-defect scores. The findings provide a local clinical reference for surgical teams, training organizations, and payers considering the procedure. Japan has aging demographics and a dense network of ISO-certified ophthalmic surgical centers, while India has substantial demand linked to ocular trauma but faces cost and specialist-capacity constraints. India’s opportunity is concentrated in metropolitan private hospitals where advanced anterior-segment expertise is available. Latin America, the Middle East, and Africa are smaller opportunities where uptake will depend on distributor coverage, referral-level ophthalmology centers, and the ability to support complex follow-up care.

List of Companies Covered in this Report:

• HumanOptics Holding AG
• REPER-NN LTD
• Morcher
• Ophtec BV

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support